GlaxoSmithKline News and Research

RSS

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

With the estimated 1.2 million people with HIV/AIDS in the United States expected to live close to a normal life span, the majority of pharmaceutical companies are not developing innovative, new long-term treatment options that offer improved efficacy, safety and tolerability when taken for decades, according to a report card on the pharmaceutical industry released today by the AIDS Treatment Activists Coalition's (ATAC) Drug Development Committee.

11 Sep 2009

Also in Global Health news: PEPFAR in Swaziland; GSK HIV patent pool; Pediatric ARVs in Uganda; PNG declares health emergency; Israeli, ECOWAS agreement; Somali children

PEPFAR on Wednesday donated eight computers to Swaziland's Ministry of Health to aid in the country's ability to track the progress of the nation's HIV/AIDS programs, the Swazi Observer reports. According to the newspaper, the computers will be distributed to regional clinics across the country (Masilela, 9/10).

10 Sep 2009

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

To continue the state life science industry’s record-setting growth rate, the North Carolina Biotechnology Center, with the help of statewide partners, is building an addition to its Research Triangle Park headquarters.

10 Sep 2009

Business vertical-focused learning solutions for the health care industry launched by TIS

Global learning solutions provider-Tata Interactive Systems (TIS)-has recently announced the launch of its first business vertical-focused learning solutions for organizations in the health care industry. TIS formally launched this initiative with the appointment of Candida Chandorkar as Vice President - Global Healthcare Solutions, a move from her earlier position as Vice President - ANZ.

10 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

The makers of Aquafresh(R) and Sensodyne(R) introduce a breakthrough technology in toothpaste - new iso-active(R) Foaming Gel. Iso-active has a revolutionary delivery system that disperses active ingredients quickly, penetrating those hard-to-reach areas of the mouth.

8 Sep 2009

CEO Cancer Gold Standard accreditation for Independence Blue Cross

Philadelphia-based Independence Blue Cross has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace.

8 Sep 2009

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Taskforce formed to help speed licensure, vaccine distribution following RTS,S trials

GNA/Peace FM examines the recent creation of a local and international taskforce to help shorten the window of time between the completion of the clinical trial of the RTS,S malaria vaccine - currently being tested across Africa - and licensure and vaccine distribution. According to the news service, scientists recently launched a Phase III trial of the RTS,S vaccine in Kintampo, Ghana, which will include 1,200 children, between the ages of 6-12 weeks and 5-17 months.

5 Sep 2009

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

Fox Chase Cancer Center has received CEO Cancer Gold Standard™ accreditation, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines.

1 Sep 2009

Glaxosmithkline affirms safety of Alli

GSK stands firmly behind the safety and efficacy of alli. Our primary priority is patient health, and we want people to know that there is no evidence that alli causes liver damage.

26 Aug 2009

Hiberix receives accelerated approval from FDA to overcome nationwide shortage

The U.S. Food and Drug Administration today approved Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years old. Hiberix is manufactured by GlaxoSmithKline, with U.S. headquarters in Research Triangle Park, N.C. and Philadelphia.

26 Aug 2009

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Santaris Pharma A/S, a privately-held biopharmaceutical company focused on developing RNA-based drugs targeted to disease-related mRNAs and microRNAs, today announced a multi-year worldwide strategic alliance with Shire plc to discover and develop new RNA-based medicines to treat rare genetic disorders.

24 Aug 2009

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

Vanderbilt University has been selected as one of 10 centers in the nation to participate in the Chemical Biology Consortium (CBC), a major new initiative to facilitate the discovery and development of new agents to treat cancer.

20 Aug 2009

FDA approves Hiberix Haemophilus influenzae type b vaccine

In response to a U.S. shortage of a vaccine to protect infants from Haemophilus influenzae type b (Hib), GlaxoSmithKline (NYSE: GSK) has received accelerated approval from the FDA (Food and Drug Administration) for Hiberix((R)) [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] as a booster dose in children 15 months through four years of age. Hib is an often severe and potentially deadly bacterial infection that can cause meningitis.

19 Aug 2009

Xceleron to acquire an Accelerator Mass Spectrometry instrument under agreement with GlaxoSmithKline

XCELERON, a leader in the field of ultra-sensitive bioanalytical studies supporting clinical research, today announced that it has signed a second Master Service Agreement with GlaxoSmithKline. Under the terms of this agreement, Xceleron will provide analytical support to GlaxoSmithKline and its affiliated research organizations. As part of the deal, Xceleron will increase capacity through the acquisition of an Accelerator Mass Spectrometry (AMS) instrument.

19 Aug 2009

GSK starts testing H1N1 vaccine; Opinion piece addresses U.S. role in helping developing countries procure vaccine

"GlaxoSmithKline has started testing its pandemic H1N1 swine flu vaccine in humans, and expects to start giving the results to government agencies next month, the drugmaker said on Friday," Reuters reports. The company "plans to conduct 16 different trials of the vaccine and to test 9,000 people in total across Europe, Canada and the United States," according to the news service (Deighton, 8/14).

17 Aug 2009

Ranbaxy receives approval to market Sumatriptan Succinate tablets

Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), and 50 mg (base).

12 Aug 2009

Researchers launch study into search-and-destroy antigen for deadly skin cancer

UT Southwestern Medical Center researchers are studying a new antigen to see whether it can track down and kill cancer cells in patients with recurring melanoma, the leading cause of skin cancer deaths.

11 Aug 2009

ISI to host eSolutions Conference in September 2009

Image Solutions Inc. (ISI), a leading provider of electronic submissions management and publishing solutions for the life sciences industry, has unveiled a prestigious line-up of speakers for its annual eSolutions Conference in Barcelona, Spain, this September to support an agenda aimed at reinventing the regulatory function.

10 Aug 2009

GlaxoSmithKline News and Research

HIV/AIDS patients in U.S. have no long-term treatment options: ATAC report card

Also in Global Health news: PEPFAR in Swaziland; GSK HIV patent pool; Pediatric ARVs in Uganda; PNG declares health emergency; Israeli, ECOWAS agreement; Somali children

North Carolina Biotechnology Center establishes Research Triangle Park headquarters

Business vertical-focused learning solutions for the health care industry launched by TIS

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

New iso-active foaming gel delivers active ingredients to hard-to-reach areas of the mouth

CEO Cancer Gold Standard accreditation for Independence Blue Cross

Third human clinical trial of LigoCyte's norovirus vaccine started

Taskforce formed to help speed licensure, vaccine distribution following RTS,S trials

Fox Chase becomes the seventh cancer center to receive the CEO Cancer Gold Standard accreditation

Glaxosmithkline affirms safety of Alli

Hiberix receives accelerated approval from FDA to overcome nationwide shortage

Santaris Pharma to discover and develop new RNA-based medicines for treating rare genetic disorders

Vanderbilt enters Chemical Biology Consortium as a Chemical Diversity Center to develop cancer treatment drugs

FDA approves Hiberix Haemophilus influenzae type b vaccine

Xceleron to acquire an Accelerator Mass Spectrometry instrument under agreement with GlaxoSmithKline

GSK starts testing H1N1 vaccine; Opinion piece addresses U.S. role in helping developing countries procure vaccine

Ranbaxy receives approval to market Sumatriptan Succinate tablets

Researchers launch study into search-and-destroy antigen for deadly skin cancer

ISI to host eSolutions Conference in September 2009

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News